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ABSTRACT
Introduction: Primary open angle glaucoma
(POAG) is a progressive optic neuropathy
characterized by impaired aqueous outflow
and extensive remodeling in the trabecular
meshwork (TM). The aim of this study was to
characterize and compare the expression
patterns of selected proteins belonging to the
tissue remodeling, inflammation and growth
factor pathways in ex vivo glaucomatous and
post-mortem TMs using protein-array analysis.
Methods: TM specimens were collected from 63
white subjects, including 40 patients with
glaucoma and 23 controls. Forty POAG TMs
were collected at the time of surgery and 23
post-mortem specimens were from
non-glaucomatous donor sclerocorneal tissues.
Protein profiles were evaluated using a
chip-based array consisting of 60
literature-selected antibodies.
Results: A different expression of some factors
was observed in POAG TMs with respect to
post-mortem specimens, either in abundance
(interleukin [IL]10, IL6, IL5, IL7, IL12, IL3,
macrophage inflammatory protein [MIP]1d/a,
vascular endothelial growth factor [VEGF],
transforming growth factor beta 1 [TGFb1],
soluble tumor necrosis factor receptor I
[sTNFRI]) or in scarcity (IL16, IL18,
intercellular adhesion molecule 3 [ICAM3],
matrix metalloproteinase-7 [MMP7], tissue
inhibitor of metalloproteinase 1 [TIMP1]).
MMP2, MMP7, TGFb1, and VEGF expressions
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were confirmed by Western blot, zymography,
and polymerase chain reaction. No difference in
protein profile expression was detected between
glaucomatous subtypes.
Conclusion: The analysis of this small TM
population highlighted some proteins linked
to POAG, some previously reported and others
of new detection (IL7, MIPs, sTNFaRI). A larger
POAG population is required to select
promising disease-associated biomarker
candidates.
Funding: This study was partially supported by
the Fondazione Roma, the Italian Ministry of
Health and the ‘‘National 5xMille 2010 tax
donation to IRCCS-G.B. Bietti Foundation’’.
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INTRODUCTION
Primary open angle glaucoma (POAG), the most
common form of glaucoma, is a multifactorial
disease with unclear pathogenesis, characterized
by retinal ganglion cell death and irreversible
damage of the optic nerve [1, 2]. Elevated
intraocular pressure (IOP) represents the main
risk factor involved in the onset and progression
of POAG, due to an imbalance between aqueous
humor production and outflow [3, 4]. POAG
trabecular meshwork (TM) displays chronic
inflammation and long-standing tissue
remodeling [5, 6]. These molecular events are
mainly of endogenous origin and related to the
long-term accumulation of oxidative damages
arising from mitochondrial failure and
endothelial dysfunction [7]. Proteins deriving
from the damage occurring in endothelial TM
cells underwent dramatic variation, reflecting
oxidative damage, mitochondrial damage,
neural degeneration, and apoptosis [8, 9].
Structural changes encompass extensive
extracellular matrix (ECM) deposition, typified
by increased collagen, fibronectin and elastin
deposition (thickness of trabecular sheets),
impaired growth factors release, unbalance in
ECM enzymes and unusual myofibroblast
development [10–15]. Apoptosis of endothelial
cells and targets of oxidative stress
(glyceraldehyde-3-phosphate dehydrogenase
[GAPDH], a glycolytic enzyme; heat shock
70 kDa protein 1 [HSP72], a stress protein; and
glutamine synthetase, an excitotoxicity-related
protein) were detected in POAG TMs,
supporting the presence of a continuous
inflammation, remodeling and immune system
activation [16, 17]. While many components of
TM ECM have been identified, only few studies
address the entire TM proteome. Cumulating
data point to impaired synthesis/release of
transforming growth factor beta (TGFbs), nerve
growth factor (NGF), vascular endothelial
growth factor (VEGF), connective tissue growth
factor (CTGF), tumor necrosis factor alpha
(TNFa), interleukin (IL)1a, IL2, IL8, fibroblast
growth factor (FGF), and their receptors,
detected by single conventional approaches
[18–22]. Some pro-inflammatory/fibrogenic
factors have been detected in the aqueous
humor, suggestive of future applications
[23–25].
To date, the mechanism and the molecular
basis responsible for structural, biochemical,
and functional changes occurring in
glaucomatous TM are poorly understood [26,
27]. Several studies have been performed to
identify systemic and local biochemical risk
factors and some novel protein/antibody
profiles have been prospected as potential
targets to counteract the degenerative effects
in POAG, in addition to the IOP [3, 4, 28].
Recently, the protein microarray approach has
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highlighted, most resourceful than
conventional approach, some candidates
(biomarkers) for POAG, pertinent to routine
diagnostic applications/monitoring of
treatment efficacy or to target therapy [18, 29,
30].
The aim of the present study was to explore
the expression of some factors in TMs from
patients with POAG.
METHODS
Ethics Statement
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national), with the Helsinki
Declaration of 1964, as revised in 2013, and was
reviewed/approved by the institutional Ethic
Committee (IRCCS IFO—Fondazione Bietti). A
written informed consent was signed by
patients joining the study and undergoing
surgical therapy.
POAG Population
A total of 40 POAG and 23 age/sex-matched
post-mortem TM specimens were used for the
study (Table 1). Both slit lamp and clinical data
were collected the day before surgery from each
patient including age, gender, ocular history,
diagnosis and duration of disease, previous
medications, IOP, visual acuity and other
ocular surgical interventions. The inclusion
criteria comprised patients who needed to
undergo trabeculectomy for uncontrolled IOP
under maximal tolerated topical medical
therapy, while the exclusion criteria comprised
patients with systemic (either inflammatory,
autoimmune and/or immunosuppressive) or
pre-existing ocular (retinal vein/artery
occlusion, diabetic retinopathy and age-related
macular degeneration) diseases, or previous
trabeculectomy or other ocular surgery or use
of topical or systemic corticosteroids. All POAG
TM samples were further grouped according to
the IOP-lowering topical therapy ongoing
before glaucoma surgery [Group 1 (n = 14):
Table 1 Patient’s main characteristics
Characteristics POAGa Control
Population 40 23
Male/female 17/23 15/8
Mean age (years) 69.25 ± 9.49 74.25 ± 7.94
Mean (±range) IOP, mm Hg 19.83 ± 4.55 –
Surgery: trabeculectomy/phacoemulsiﬁcation 11/29 Noneb
Previous therapyc IOP-lowering eye drop None
All data are shown as mean ± standard deviation
IOP intraocular pressure, POAG primary open angle glaucoma
a Both inclusion and exclusion criteria are detailed in the ‘‘Methods’’ section
b The non-glaucomatous control TMs were dissected out by mimicking trabeculectomy and phaco-trabeculectomy surgery
on sclerocorneal specimens (EyeBank)
c Medications are listed in the ‘‘Methods’’ section
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prostaglandin analogs (PGE) ? carbonic
anhydrase inhibitors (CAI); Group 2 (n = 26):
PGE ? CAI ? beta-blockers (BB)].
All analytical grade reagents and sterile
plastic-ware were from SERVA (Weidelberg,
Germany), ICN (Costa Mesa, CA, USA),
Euroclone (Milan, Italy), Sigma-Aldrich (St.
Louis, MO, USA) and NUNC (Roskilde,
Denmark), unless otherwise specified.
Ultrapure Milli-Q Grade Water was daily
provided by the DirectQ 5 apparatus
(Millipore, Vimodrone, Italy).
POAG and Post-mortem TM Specimens
Pathological TMs were collected from patients
who underwent surgical procedures (n = 10
from trabeculectomy and n = 25 from
phacotrabeculectomy) and quickly stabilized
in a storage buffer (50 mM Tris-buffer, 150 mM
NaCl, 1 mM EDTA, 10% glycerol) supplemented
with protease inhibitors (#78410; Pierce
Biotechnology, Rockford, IL) and stored at
-70 C. Delivery to the Laboratory Unit was
performed according to a standardized
procedure, avoiding sample thawing and
protein degradation.
Control samples, made available by the Eye
Bank of Rome (Italy), were obtained from organ
donors undergoing removal of eyes for corneal
transplant, within 6 h of death and provided in
Eusol-Cmedium (herein shorten as post-mortem
samples). The absenceof any eyediseases in these
donorswas ascertained in agreementwith Italian
national law (No. 301 of 12August 1993). Briefly,
four representative TMs were collected for each
specimenunder adissectormicroscope (SMZ645;
Nikon, Tokyo, Japan) equipped with cold-light
optic fibers (PL2000 photonic; Axon, Vienna,
Austria), reproducing accurately theprocedureof
trabeculectomy and quickly stored in
inhibitor-supplemented storage buffer at
-70 C until using in parallel with POAG
samples. All post-mortem TMs were quickly
stabilized in appropriate buffer, similar to
POAG specimens.
Additional 5 glaucomatous (n = 2 from
trabeculectomy and n = 3 from
phacotrabeculectomy) and 5 post-mortem
specimen were sampled in Thin Prep (Cytyc
Corp., Milan, Italy) and subjected to molecular
analysis.
Total Protein Extraction and Sodium
Dodecyl Sulphate—Polyacrylamide Gel
Electrophoresis, (SDS-PAGE) Analysis
Enzymatic pre-digestion was used to extract
protein from each specimen (n = 35 POAG and
n = 18 post-mortem samples). Briefly, TM
specimens were treated with dispaseII (2 lg/mL
in HBSS without Ca2? and Mg2?) for 15 min at
37 C, diluted 1:1 (v/v) with 29 Lysis buffer
(25 mM Tris-buffer, 150 mM NaCl, 0.1%
Tween20, 1 mM EDTA, 10% glycerol, 0.1%
SDS, 10 mM NaF and 1 mM PMSF; pH 7.5),
homogenized with a Polytron (25 s/0 C at
21500 rev./min; Ultra Turrax T25 basic;
IkaWerke, Staufen, Germany) and briefly
sonicated to shear DNA/RNA (VibraCell,
Sonics, Newtown, CT, USA). Tissue lysates
were clarified by centrifugation and protein
amount/quality was analyzed using the
Nanodrop Spectrophotometer (A1000; Celbio,
Milan, Italy). Protein amounts were detected
with the A280-Nanodrop option by means of
common internal standards, after ‘‘blank’’
options against water and extraction buffer.
Data (lg/lL) were used to normalize protein
extracts before loading in the specific assay.
SDS-PAGE was performed under reducing
(electrophoretic profile) conditions on a
4–12% precasted-SDS mini gel (MiniProtean III
apparatus; Biorad Laboratories Inc, Hercules,
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CA, USA). Separated bands were transblotted to
Hybond membranes (Amersham Biosciences;
GE Healthcare, Buckinghamshire, England)
under semidry conditions (Transblot
apparatus; Biorad). Membranes were stained
with the Ponceau S solution (SERVA).
Whenever required, protein extracts were
concentrated according to the 500 VivaSpin
manufacturers’ recommendations (Sartorius
AG, Goettingen, Germany). Some samples
were subject to IgG removal according to a
standard procedure (GE Healthcare) [31].
Chip-Based Arrays for Proteome Analysis
The proteome array was performed on
customized chip-based arrays provided on
glass-slides, according to the manufacturers’
procedures with minor modifications (RayBio
technology; Norcross, CA). Each glass-slide
(array) comprised 14 identical subarrays
containing 60 biomarkers assembled on
demand. The scheme of each chip is reported
in Fig. 2a. Inter-assay normalization was
conducted by including multiple positive
markers and negative controls for each
sub-array. The minimum sensitivity range for
detection of each protein varied, ranging from
3.8 to 56 pg/mL.
For hybridization, an equal amount of
protein extracts (350 ng/mL in Lysis Buffer)
was applied to each sub-array (70 lL/subarray).
Both POAG (n = 25 POAG) and control (n = 13)
extracts were processed in parallel. After an
overnight incubation at 4 C, the array slides
were washed and exposed to a biotinylated
antibody mixture followed by a
cy3-streptAvidin labeling solution. All steps
were performed under orbital shaking
(CertomaxII, Sartorius AG) and all the
hybridization/washing solutions were provided
by the kit. As a final point, the glass-slides were
washed once with MilliQ water, spin-dried and
acquired with a GenePix 4400 Microarray
scanner (Molecular Devices LLC, Sunnyvale,
Silicon Valley, CA). To obtain appropriate Cy5
(background signal) and Cy3 (specific signal)
images, the slides were scanned over previously
validated acquisition parameters and the
images/arrays (blocks) were uniformly adjusted
for size, brightness and contrast at the moment
of acquisition. Using the SPOT tool, the specific
area (corresponding to each cytokine on the
array) was manually spotted and automatically
adjusted, according to prefixed acquisition
parameters applied to all glass-slides of the
study. The fluorescent intensity data (FI) of
each spot was calculated by the GenePix Pro 6.0
pro software (Molecular Devices), that provide
background-subtracted FI data (F532-B532, N
factor) as of a value for spot volume
representing the product of the area and the
highest pixel value contained in that area.
Confirmation Experiments by Western
Blot, Zymography, and Real-Time PCR
Western Blotting
The membranes from electrophoretic analysis
were equilibrated in 0.5% Triton, blocked in 3%
BSA, incubated with the primary antibodies
(0.2–0.8 lg/mL, 18 h; MMP2 (sc-10736) and
MMP7 (sc-130819) were from Santa Cruz;
TGFb1 (mab240) and VEGF (AF-293-NA) were
purchased from R&D Systems, Minneapolis, Il)
and labeled with secondary specie-specific
POD-conjugated antibodies (1/7000, 90 min;
Jackson Laboratories, West Grove, PA). The
specific signals were visualized by SuperSignal
West Pico Trial (Pierce).
Zymography
To study MMP2 and MMP9 functional activity,
tissue extract were three fold-concentrated
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(VivaSpin) and pre-mixed with 5X Loading
buffer under non-reducing conditions and
incubated at 37 C over 30 min. Normalized
protein extracts (20 lL/lane) were pre-incubated
at 37 C over 30 min. Samples were then
fractioned on 7–10% SDS-PAGE gels
containing 0.1% gelatin (1 mg/mL gelatin),
under non-reducing condition (frontline/
130 V). Gels were washed in rinse-buffer
(15 min; 50 mM Tris–HCl, 10 mM CaCl2 and
2.5% Triton X-100; pH 7.2) to promote recovery
of protease activity and briefly rinsed with
distilled water before incubating in substrate
buffer (24 h/37 C; 50 mM Tris–HCl, 150 mM
NaCl, 10 mM CaCl2, 1% Triton-X100; pH 7.2).
Gels were stained with 0.5% Coomassie blue
R-250 in 30% isopropanol and 10% acetic acid
for 30 min to 2 h and then de-stained in 10%
isopropanol and 10% acetic acid until clear
bands were visible. Internal controls and size
marker were run in parallel. Molecular weights
of the bands were estimated through the use of
prestained molecular-weight markers MMP2
and MMP9 activity was identified as clear
bands (white bands over a blue background)
corresponding to degraded substrate.
Membranes and zymograms were captured
in a 1D Kodak Image station (Kodak 550,
Eastman Kodak Company, Sci. Imaging
Systems, Rochester, NY, USA) and exported as
16-tiff converted images (1D Kodak Image
Analysis Software). Single integrated optical
density values (Intdensity) were registered for
each group by means of 1D ImageJ software
(ImageJ ver. 1.43; NIH-http://rsb.info.nih.gov/
ij/) and assembled with minor modifications by
Adobe photoshop 7.0 (Abacus concepts).
Real-Time PCR
RNA extraction was performed by Proteinase K
predigestion and EuroGold TRIfast extraction,
according to the manufactures’ procedure
(EuroClone, Pero, Milan, Italy). Equivalent
total RNAs (170 ng; 260/280 rate[1.8;
Nanodrop) were used for cDNA synthesis that
were carried out using 50 pM random primers
and 200 U Reverse Transcriptase (IM-PROM kit,
Promega, Milan, Italy) in a programmable PCR
thermocycler (Primus 25 advanced-PCR; Peqlab
LLC., Wilmington, USA). SYBR Green PCR
amplifications (Applied Biosystems, Foster
City, CA, USA) were run in a PCR Opticon2
(MJ Research, Watertown, MA), according to a
standard protocol. The specific primers used
were as follows: MMP2, MMP7, TGFb1, VEGF,
18S, H3, and b2MG). Negative/positive controls
and single-mode melting curves were used to
validate the amplifications.
Statistical Analysis
POAG and post-mortem TMs were analyzed in
duplicate (spots/bands) and mean values (±SD)
were calculated from these replicates. Individual
biomarker expression was provided by GenePix
software. The row spot intensity data were
entered into a Microsoft Excel database
(Microsoft, Redmond, WA) and duplicate spots
outside the 10% coefficient of variability were
refused from the statistical analysis. FDR value
of 0.01, as observed. Protein response ratios
were defined as the variation in a given marker
and a cut-off of two fold (changes) was used for
differential expression, in accordance with
previously published methods [32, 33]. The
non-parametric Mann–Whitney U test was
selected according to the small size
population. Statistical significance for
intra-pair POAG analysis was set at p\0.00083
to control for multiple testing (p = 0.05/60
targets) and at p B 0.05 for WB, Zymography
and real-time PCR. The SPSS 15.0 statistic
package (SPSS Inc, Chicago, IL, USA) was used
for all comparisons. A specific REST/
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Mann–Whitney U test coupled analysis was
carried out for PCR experiments.
RESULTS
A total of 40 POAG and 23 post-mortem TM
specimens were analyzed (Table 1). As detected
in pilot studies, 17% (8/40 extracted specimens)
of the total TM extracted samples was
undetectable. The entire experimental
procedure of this lower-case project,
procedure, including TM stabilization to
reduce protein degradation during transit, is
shown in Fig. 1a. The total protein amount was
detectable in all specimens included in the
study, and representative spectrophotometer
plots are shown in Fig. 1b. The electrophoretic
analysis of POAG TM revealed the presence of
Fig. 1 Experimental procedure and total protein analysis.
a POAG and post-mortem TM specimens were
simultaneously processed, according to the procedure
reported in the ‘‘Methods’’ section. b Representative A280
plot showing the digital spectrophotometer outputs. Small
peaks in the tract represent a small proportion of
contaminants (solvents and salts; left side). c Comparative
TM protein proﬁles by 1D SDS-PAGE analysis
(representative membrane), from randomly selected POAG
and post-mortem specimens generated after the enzymatic
digestion procedure. Note the presence of bands resembling
IgG proteins. POAG primary open angle glaucoma,
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel
electrophoresis, TM trabecular meshwork
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Fig. 2 Representative chip-based arrays. Chip are grids that
contain small amounts of puriﬁed proteins in high density,
hybridized to sample and detected by ﬂuorescent technique.
a The map showing the selected factors in a 14 9 10 grid.
Each subarray contains 60 antibodies and speciﬁc positive/
negative referring spots. b, c Representative GenePix
acquired arrays from POAG (b) and post-mortem
(c) TM specimens, both loaded as normalized extracts.
White points are positive technique controls (framed), dark
points are negative technique controls and green points are
POAG/post-mortem TMs (cy3-labeled spots).
Abbreviations of the main factors were according to
International Classiﬁcation. EGF epidermal growth factor,
IL interleukin, MIP macrophage inﬂammatory protein,
MMP matrix metalloproteinase, POAG primary open angle
glaucoma, SCF stem cell factor, SDS sodium dodecyl
sulphate, TIMP tissue inhibitor of metalloproteinase, TLR
toll-like receptor, TM trabecular meshwork, TNF tumor
necrosis factor
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abundant bands at the 100, 90, 70 and 40 kDa.
Both heavy and light IgG chains were observed
in several protein extracts (SDS-PAGE; Fig. 1c)
and samples showing over-expressed
heavy/light Ig chains were pretreated prior to
hybridization (see M&M).
To facilitate the reading/analysis of
chip-array grids in Fig. 2a, appropriate clusters
were defined. Two representative cy3-labeled
fluorescence subarrays are reported in Fig. 2b, c,
showing a significant increase of IF in POAG
subarrays (B) with respect to post-mortem ones
(C). The non-parametric Mann–Whitney
two-sided U test was employed to select factors
of significant value. The full data are available in
Table 2, including single fold cut-offs and
p values ([two fold changes and p B 0.00083)
provided in clusters as follows: cytokines;
neurotrophins, fibrogenic and angiogenic
factors; chemokines/adhesion molecules; ECM
metabolism, metalloproteinases and
tissue-inhibitory factors and other molecules,
including soluble receptors and some referring
proteins. A total of 32 out of 60 potential
candidates were significantly associated with
POAG. Most of them were represented by
cytokines (IL10, IL6, IL5, IL7, IL12p40/70),
chemokines (VCAM1, MIP1a/d) and growth
factors (TGFb1, VEGF), showing high
expression levels ([five fold) in POAG TMs, as
compared to non-glaucomatous ones
(p\0.00083; Mann–Whitney U test).
Moreover, IL16, IL18 and ICAM3 showed
negative values, as compared to controls
(p\0.00083; Mann–Whitney U test).
Regarding the ECM enzymes, a significant
expression was detected for MMP2 while a low
expression was quantified for MMP7 and TIMP1
([two fold changes; p\0.00083;
Mann–Whitney U test). No difference in
protein profile expression was observed
between the two IOP-lowering subgroups
(Group 1 and Group 2; p[0.00083,
Mann–Whitney U test), nor between the two
different surgical approaches (trabeculectomy
and phacotrabeculectomy; p[0.00083,
Mann–Whitney U test).
To better understand ECM metabolism and
fibrosis/angiogenesis in glaucomatous TMs,
MMPs 2/9/7 and TIMP1 as well as TGFb1,
VEGF were selected for Western Blot,
Zymography and real-time PCR analysis. The
Western Blot analysis showed as follows:
increased expression for MMP2 (?1.39 ± 0.02
folds; p\0.05), TGFb1 (?2.00 ± 0.53 folds;
p\0.05) and VEGF (?2.13 ± 0.41 folds;
p\0.05); unchanged expression for MMP7
(?0.50 ± 0.39 folds; p[0.05); and decreased
expression for MMP9 (-3.71 ± 2.54 folds;
p\0.05), TIMP1 (-1.43 ± 0.33 folds; p\0.05).
Zymography (a functional test) identified bands
of gelatinolytic activity, respectively, at 66 and
72 kDa, corresponding to the active and pro
MMP2, respectively, at 80 and 92 kDa,
corresponding to the active and pro MMP9
(Fig. 3). A high MMP9 gelatinolytic activity was
also detected in non-glaucomatous control
extracts (post-mortem specimens). Finally, the
relative real-time PCR supported (p\0.05) the
increased expression of MMP2 (?2.53 ±
0.022log-ratio), TGFb1 (?5.27 ± 0.032log-ratio) and
VEGF (?2.84 ± 0.162log-ratio), and highlighted
the deregulation of MMP7
(-3.77 ± 0.062log-ratio).
DISCUSSION
POAG represents one of the major leading
causes of blindness worldwide, with poor early
diagnosis and prognosis [1, 2, 28, 34].
Currently, no therapy is curative and an early
diagnosis and/or a prompt intervention in ‘‘risk
patients’’ would contribute significantly to
reduce the progression of disease [1, 2, 24].
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Table 2 Protein proﬁle expression
Protein Folds p value
Cytokines
IL10 23.81 2.84E-07
IL6 14.57 2.84E-07
IL5 13.27 2.84E-07
IL7 12.51 2.84E-07
IL12p70 8.74 2.84E-07
IL12p40 7.72 2.84E-07
IL3 4.43 2.84E-07
IL21 3.71 2.84E-07
IL4 3.70 2.84E-07
IL33 3.25 2.84E-07
TNFa 2.48 5.52E-07
cIFN 2.28 5.52E-07
IL15 2.22 2.84E-07
IL2 2.14 5.52E-07
IL1b 1.71 1.10E-04
IL17 1.64 1.06E-05
IL8 1.45 3.18E-06
IL34 1.34 1.70E-03
IL9 1.01 NSS
IL18 -11.79 2.16E-05
IL16 -43.65 5.03E-06
Neurotrophins, ﬁbrogenic, and angiogenic factors
VEGF 6.10 9.01E-07
TGFb1 6.07 2.84E-07
NT3 4.73 3.08E-07
bFGF 3.92 1.84E-04
bNGF 3.84 2.84E-07
Insulin 3.33 1.46E-06
BDNF 3.13 2.84E-07
NT4 2.96 2.84E -07
SCF 1.32 NSS
Table 2 continued
Protein Folds p value
EGF -1.51 NSS
ECM metabolism
MMP2 3.18 2.84E-07
MMP1 2.00 2.84E-07
TIMP2 1.79 5.03E-06
MMP13 1.27 NSS
TIMP4 -1.28 NSS
MMP9 -1.35 NSS
MMP7 -2.03 2.81E-04
TIMP1 -2.18 8.76E-04
Chemokines/adhesion molecules
VCAM1 7.29 2.84E-07
MIP1d 7.04 3.35E-07
MIP1a 5.51 2.84E-07
Eotaxin1 2.61 3.18E-06
ICAM1 2.16 1.51E-05
TACE 2.01 2.84E-07
RANTES 1.94 1.23E-03
ICAM2 1.91 1.88E-05
Eotaxin2 1.69 NSS
MIP3b 1.50 5.83E-03
NCAM1 1.46 NSS
MIP3a -1.14 NSS
MIP1b -1.73 1.84E-04
ICAM3 -8.90 6.50E-07
Other molecules
sTNFR I 4.41 4.68E-07
Albumin 1.84 NSS
S100B 1.80 5.83E-03
IP10 1.77 1.41E-05
sTNFR II 1.03 NSS
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Sustained high-IOP levels or recurrent TM
inflammation/remodeling or even
long-standing homeostatic adjustments could
trigger atypical cell–cell, cell–protein and/or
protein–protein interactions, leading to TM
structural changes in POAG [17, 35]. Several
genes/proteins (soluble and stress-related
mediators, growth factors, cytoskeletal and
ECM-associated proteins) have been identified
in POAG (mainly in TM-derived cells, aqueous
humors, tears and blood) and proposed as
potential candidates for the prognosis of
disease and monitoring of therapy [24, 36].
Since any effort in the characterization of
POAG-associated protein profile will be of great
importance in understanding the mechanisms
underlying POAG progression, a nonbiased
chip-based microarray approach was carried
out to discriminate 60 antibodies for potential
proteins/factors relevant to pathological TM.
The selected potential candidates are all known
to be involved in chronic inflammation and
tissue remodeling [16, 24, 28, 31, 36–39].
To the best our knowledge in literature, this
is the first study conducted in vivo on human
normal and glaucomatous TMs. From this
comparative analysis, 32 out of 60 explored
candidates were significantly affected in POAG
specimens, as compared to control specimens
dissected out from non-glaucomatous
Table 2 continued
Protein Folds p value
TLR2 -1.21 3.26E-01
Mann–Whitney U test analysis with both POAG/ctr
fold-changes (C2) and p values (B0.00083, see ‘‘Methods’’
section) for each biomarker in POAG TMs. NSS for
results having p values[8.3E-04. The factors are listed for
higher to lower expression. The ECM metabolism cluster
included both metalloproteinases and their speciﬁc
inhibitors, and the cluster other molecules comprised
soluble receptors and some referring proteins
BDNF brain-derived neurotrophic factor, ECM
extracellular matrix, EGF epidermal growth factor, FGF
ﬁbroblast growth factor, ICAM intercellular adhesion
molecule, IFN interferon, IL interleukin, IP interferon
gamma-induced protein, MIP macrophage inﬂammatory
protein, MMP matrix metalloproteinase, NCAM neural
cell adhesion molecule, NGF nerve growth factor, NSS not
statistically signiﬁcant, NT neurotrophin, POAG primary
open angle glaucoma, RANTES regulated on activation,
normal T cell expressed and secreted, SCF stem cell factor,
sTNFR soluble tumor necrosis factor receptor, TACE
TNF-a converting enzyme, TLR toll-like receptor, TIMP
tissue inhibitor of metalloproteinase, TNF tumor necrosis
factor, TM trabecular meshwork, VCAM vascular cell
adhesion molecule, VEGF vascular endothelial growth
factor
Fig. 3 Conﬁrmation of gelatinolytic activity of MMPs.
Non-glaucomatous post-mortem and POAG TM (n = 7;
lanes 1–7) extracts were electrophoresed on a gelatin-
containing SDS gels (see the ‘‘Methods’’ section). Note the
presence of gelatinolytic activity at 80/92 kDa (active/pro
MMP9) and 62/72 (active/pro MMP2). Representative
zymogram from three similar experiments. Both 80 and
92 kDa MMP9 bands are clearly visible in control TMs.
Distinct 62 and 72 kDa bands speciﬁc for MMP2 were
not detected in post-mortem extracts, while speciﬁc bands
occur in POAG extracts. MMP matrix metalloproteinase,
POAG primary open angle glaucoma, TM trabecular
meshwork
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sclerocorneal explants mimicking the surgical
procedure (see Table 2). Particularly, some
cytokines (IL10, IL6, IL7, IL12p40/70, VCAM1,
MIP1d/a, sTNFRI) as well as Th1/Th2- (IL2, IL3,
IL4, IL5) and tissue remodeling- (MMP2, VEGF,
TGFb1) related proteins were significantly
increased. This increase would suggest the
presence of both chronic inflammatory and
tissue remodeling process in these
glaucomatous TM specimens. The observation
of increased TNFa, cIFN, IL2, IL3, IL4, IL5, IL7,
IL12p40/70 and VCAM1 expression in TM
specimens is in line with previous single and
multiparametric conventional approaches
performed in human TM-derived primary
cultures, aqueous and tears [17, 24, 35, 40].
During glaucoma, macrophages produce
cytokines including IL6, IL1b and TNFa,
leading to an acute inflammatory response.
These cytokines can induce ECM remodeling
and alter cytoskeletal interactions in the
glaucomatous TM [20]. The increased
expression of IL6 and IL10 in glaucomatous
TMs is in line with the increased IL10 and IL6
levels detected, respectively, in glaucomatous
fluids (sera and aqueous) and strongly support
the hypothesis of IL10 and IL6 as potential
biomarkers of prognosis of disease or therapy
[25, 40–43]. The high expression of IL6 might be
explained with the remodeling process
occurring in glaucomatous TMs and the
IL6-TGFb1 cross talk observed in TM-derived
primary cultures [40, 43, 44]. IL6 increased
outflow facility in perfused anterior segments
of porcine eyes and IL6 levels were increased in
porcine TM cells as a result of oxidative
challenge [45, 46]. Besides, IL6 and IL8 have
been implicated in induction of cellular
senescence [47]. TNFa and IL6 mediate human
microvascular endothelial tight junction
modulation, by their ability of cytoskeletal
rearrangment [48]. Finally, IL8 was found to
modulate the permeability of the Schlemm’s
canal endothelial cells [49].
On the other hand, the increase of IL7 might
be explained with the IL7 ability to counteract
the TGFb1 activity, as observed in other in vitro
models [50]. By contrary, the high IL10
expression is actually missing of explanation,
although in experimental models of fibrosis the
IL10 triggered (i) the anti-inflammatory
response through the inhibition of TNFa, IL1,
IL6, IL8, IL12, MIP1a and MIP2a release from
monocytes/macrophages (anti-inflammatory
response), (ii) the macrophage activity
(down-regulating response MMPs/TGFb1) and
(iii) the up-regulation of TIMPs [43, 51].
Of interest, the significant increase of MIP1a/
d and decrease of MIP1b as well as the increase
of VCAM1 and decrease of ICAM3 might
support the presence of an anti-inflammatory
response, as observed in other systems [52]. As
for IL10, the increase of MIPs might be involved
in the modulation of macrophage migration,
the activation of granulocytes and the
modulation of IL5, IL3, IL4 and IL12
inflammatory/profibrogenic activity [52]. The
high sTNFRI expression might represent a point
of interest, since it has been recently reported
that this soluble receptor might be involved in
the regulation of TNFa receptor activity [53].
With respect to the significant low expression of
IL18 and IL16 actually we have no explanation.
The observation of the overexpression of IgG
bands in the electrophoretic profiles might
suggest the contribution of B cell implying
potential neuroprotective effects, as previously
described [31, 54, 55].
Although cumulating data indicate that
MMPs and their inhibitors are increased in
TMs’ tissue and derived cells, our data show
no significant variation in MMPs/TIMPs
expression, except for MMP2 and TIMP1. This
finding might be consistent with a
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steady-fibrotic status and/or the presence of
some inhibitory feedbacks due to endogenous/
exogenous factors [56]. Physiological ECM
remodeling occurs via a tight cross talk
between MMPs and their tissue-related
inhibitors (TIMPs) [6]. The increased MMP2,
the unchanged MMP9/MMP13 and the
decreased MMP7/TIMP1 expression might be
the result of an excessive ECM accumulation
and a low proteolytic activity [6, 7, 10]. One
explanation for this result might be the
overexpression of VEGF/TGFb1 (profibrogenic
factors), IL7 (inhibitor of fibrosis) and/IL6/IL12/
IL10/IL5/IL4/IL3 (profibrogenic cytokines), all
directly/indirectly involved in the tissue
remodeling process [20, 21, 57, 58]. Another
explanation might lie in the eye-drop therapy,
since in addition to endogenous factors and
ECM-derived products, the exogenous
medications might influence TM remodeling,
representing a side-effect of the therapy [56].
Both endogenous (increased IOP) and
exogenous-induced (medications)
biomolecular changes might actively
contribute to the biomechanical features of
obstructive TM. It is noteworthy to highlight
that the therapy usually starts with medications
for reducing IOP in order to delay/prevent
glaucoma progression [55]. Hence, our POAG
population is represented by patients
chronically treated with IOP-lowering
eye-drops and not undergoing previous
surgery. Therefore, the possibility that TM
specimens collected at the time of
trabeculectomy might express a protein profile
potentially influenced by the topical therapy
cannot be excluded. It should be also noted that
in this study population no corticosteroids/
antibiotics therapy was used before
trabeculectomy. It is well known that the
therapy can alter gene expression of the TM
influencing the results of our research, but this
is what really happens in all glaucoma patients
who daily use antiglaucoma drugs to counteract
the development of the disease [59]. Therefore,
although it is not possible (in this study) to
eliminate the influences and interference of
therapy, the proteins found reflect the real
profile of glaucomatous proteome.
Altogether the protein chip-based array
indicates some new factors (IL7, MIPs,
sTNFaRI) and confirm some old ones (IL10,
IL6, IL5, IL12, VEGF, TGFb1 and NGF), all
indicative of an active inflammatory process,
as previously described [60, 61]. Indeed, both
protein and mRNA evaluations highlight the
presence of an active process of tissue
remodeling and angiogenesis (MMP2, MMP7,
VEGF, TGFb1). Current studies are underway to
correlate this glaucomatous TM expression with
those of some glaucomatous body fluids
(aqueous, tears and blood).
CONCLUSION
The possibility to define some factors in
glaucomatous TMs potentially associated with
disease and correlate this expression in
glaucomatous body fluids represents a step
forward in the management of glaucoma.
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